Table 3.
Cancer risk following AIDS-defining and non-AIDS-defining lymphoid malignancies among HIV-infected people.
| Cancers | Number of cancers (N) | AIDS-defining lymphoid malignancy | Non-AIDS-defining lymphoid malignancy | ||
|---|---|---|---|---|---|
| Number with first primary lymphoid malignancies N (row %) |
aHR (95% CI)a | Number with first primary lymphoid malignancies [N (row %)] |
aHR (95% CI)a | ||
| Any first nonlymphoid cancer | 18 944 | 139 (0.7) | 1.7 (1.5–2.0) | 87 (0.5) | 2.0 (1.6–2.5) |
| Oral cavity | 511 | 6 (1.2) | 2.4 (1.1 −5.4) | 1 (0.2) | ... |
| Colon | 601 | 5 (0.8) | 2.5 (1.0–6.0) | 2 (0.3) | ... |
| Rectum | 549 | 3 (0.6) | 1.2 (0.4–3.8) | 7 (1.3) | 5.5 (2.6–11.6) |
| Anus | 1744 | 16 (0.9) | 1.9 (1.1 −3.1) | 16 (0.9) | 4.0 (2.4–6.6) |
| Liver | 1377 | 7 (0.5) | 1.5 (0.7–3.2) | 6 (0.4) | 2.1 (0.9–4.6) |
| Lung | 3111 | 13 (0.4) | 1.1 (0.6–1.8) | 11 (0.4) | 1.5 (0.8–2.7) |
| Kaposi sarcoma | 2379 | 37 (1.6) | 2.3 (1.6–3.1) | 7 (0.3) | 1.3 (0.6–2.8) |
| Female breast | 873 | 1 (0.1) | … | 4 (0.5) | 2.8 (1.1 −7.5) |
| Prostate | 1803 | 1 (0.1) | … | 6 (0.3) | 1.3 (0.6–2.8) |
| Kidney | 441 | 4 (0.9) | 2.6 (1.0–7.1) | 1 (0.2) | ... |
| Myeloid malignanciesb | 447 | 11 (2.5) | 6.2 (3.4–11.3) | 8 (1.8) | 8.3 (4.1–16.8) |
| Miscellaneousc | 1237 | 16 (1.3) | 3.2 (2.0–5.3) | 3 (0.2) | 1.1 (0.4–3.4) |
Highlighted aHRs and 95% CIs indicate estimates that were statistically significant with P < 0.05. (…) Hazard ratios were suppressed for comparisons when there were ≤2 nonlymphoid cancers with prior lymphoid malignancies. Cox regression models had age as the time scale. aHR, adjusted hazard ratio; CI, confidence interval.
Models adjusted for sex/risk group, race/ethnicity, calendar year of cohort entry, and prior AIDS diagnosis and time since HIV diagnosis as time-varying covariates.
Myeloid malignancies include myelodysplasia, myeloproliferative neoplasms, and other myeloid malignancies.
Miscellaneous cancers include cancers of the following sites: salivary glands (N = 32), other oral cavity/pharynx (N = 85), small intestine (N = 70), other gastrointestinal tract (N = 33), other respiratory tract (N = 49), bone and cartilage (N = 77), male breast (N = 32), other female genital tract (N = 88), other male genital tract (N = 25), eye and orbit (N = 39), other urinary tract (N = 21), other endocrine glands (N = 26), and unknown primary site (N = 660).